)
Edge15 May 2026
TOMRA: Closing the Loop
The story of TOMRA: from reverse vending machine pioneer to global technology for deposit systems, recycling, and resource optimization.
TG Therapeutics
TG Therapeutics (TGTX) investor relations material
TG Therapeutics Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary6 May, 2026
Executive summary
Q1 2026 delivered record-setting results, with global revenue reaching $205 million and U.S. BRIUMVI net revenue at $195 million, up 63% year-over-year, driven by strong demand and commercial execution.
Over 25,000 patients have been prescribed BRIUMVI globally, marking a shift from early adoption to a growing installed base.
Full-year 2026 global revenue guidance raised to $925 million; U.S. BRIUMVI revenue guidance increased to $885–900 million.
A new $750 million senior secured credit facility was secured, repaying the prior $250 million facility and providing additional liquidity.
Strategic focus remains on expanding BRIUMVI's reach through lifecycle programs, pipeline advancement, and disciplined capital allocation.
Financial highlights
Q1 2026 net product revenue was $201.3 million, up from $119.7 million in Q1 2025; total revenue reached $205 million, including $3.6 million in license, royalty, and other revenue.
Operating income reached $34.8 million, compared to $8.6 million in Q1 2025.
Net income was $19.8 million ($0.12 per diluted share), up from $5.1 million ($0.03 per share) a year ago.
Cash, cash equivalents, and investment securities totaled $572.8 million as of March 31, 2026.
Share buybacks totaled $100 million in Q1, with the program expanded to $300 million.
Outlook and guidance
Full-year 2026 global revenue guidance raised to $925 million; U.S. BRIUMVI revenue guidance increased to $885–900 million.
Q2 2026 U.S. BRIUMVI net revenue guidance set at approximately $220 million.
Full-year operating costs expected at $350 million (excluding stock-based comp), plus $100 million for subcutaneous manufacturing and secondary manufacturer startup.
Topline data from the Phase 3 subcutaneous BRIUMVI trial expected by year-end 2026 or Q1 2027, with commercial launch targeted for 2028 pending regulatory approval.
Existing cash, equivalents, and projected revenues expected to fund operations for more than twelve months.
Subcutaneous BRIUMVI manufacturing cost guidance
Azer-cel Phase 1 data timing in Progressive MS
Neuraxpharm royalty and sales contribution in Q1
Clinical impact of wearing off symptoms data
Strategic expansion into the subcu MS segment
Capital allocation: share buybacks versus BD
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from TG Therapeutics
- Annual meeting to elect directors, ratify auditor, and approve pay, with strong governance focus.TGTX
Proxy filing1 May 2026 - 2025 revenue soared 92% on BRIUMVI growth, with strong 2026 guidance and global expansion.TGTXQ4 20259 Apr 2026
- Q2 BRIUMVI sales soared 350%+, driving raised guidance, profitability, and new capital moves.TGTXQ2 20242 Feb 2026
- BRIUMVI's rapid adoption and pipeline expansion position it for CD20 market leadership.TGTXGoldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026
- Briumvi drives MS market growth, with new patents, pipeline expansion, and a subQ version in development.TGTXJefferies 2024 Global Healthcare Conference1 Feb 2026
- Briumvi Q3 revenue up 230% year-over-year; full-year guidance raised to $300–$305M.TGTXQ3 202417 Jan 2026
- Briumvi's growth accelerates with new formulations, strong sales, and pivotal data expected in 2026.TGTX44th Annual J.P. Morgan Healthcare Conference13 Jan 2026
- BRIUMVI outperforms expectations as SubQ and CAR-T pipeline advances, with new manufacturing underway.TGTX7th Annual Evercore ISI HealthCONx Healthcare Conference12 Jan 2026
- Robust sales, innovation, and pipeline expansion drive leadership in the CD20 market.TGTX43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
Next TG Therapeutics earnings date
Q2 20263 Aug, 2026
TG Therapeutics
Next TG Therapeutics earnings date
Q2 20263 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage